Patents by Inventor Oliver Simic

Oliver Simic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240051954
    Abstract: The present disclosure relates to a compound of Formula (I): (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein Ring A, and R1 through R4 are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: December 20, 2021
    Publication date: February 15, 2024
    Inventors: David CARCACHE, Florian GRUBER, Danilo GUERINI, Martin GUNZENHAUSER, Richard HENG, Francesca PERRUCCIO, Oliver SIMIC, Carsten SPANKA
  • Publication number: 20230085472
    Abstract: The present disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1 through R8 are as defined herein, and methods of making and using the same.
    Type: Application
    Filed: December 20, 2021
    Publication date: March 16, 2023
    Inventors: David CARCACHE, Florian GRUBER, Danilo GUERINI, Martin GUNZENHAUSER, Richard HENG, Francesca PERRUCCIO, Oliver SIMIC, Carsten SPANKA
  • Publication number: 20200289514
    Abstract: The present invention describes new pyrazolo-pyrimidine derivatives which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.
    Type: Application
    Filed: November 11, 2016
    Publication date: September 17, 2020
    Inventors: Karen KAMMERTOENS, Jean QUANCARD, Achim SCHLAPBACH, Oliver SIMIC, Marina TINTELNOT-BLOMLEY, Grahame WOOLLAM
  • Patent number: 10442808
    Abstract: The present invention describes new pyrazolo-pyrimidine derivatives according to Formula (I) which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: October 15, 2019
    Assignee: Novartis AG
    Inventors: Carole Pissot Soldermann, Jean Quancard, Achim Schlapbach, Oliver Simic, Marina Tintelnot-Blomley, Thomas Zoller
  • Publication number: 20180030061
    Abstract: The present invention describes new pyrazolo-pyrimidine derivatives which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.
    Type: Application
    Filed: October 11, 2017
    Publication date: February 1, 2018
    Inventors: Carole Pissot Soldermann, Jean Quancard, Achim Schlapbach, Oliver Simic, Marina Tintelnot-Blomley, Thomas Zoller
  • Patent number: 9815842
    Abstract: The present invention describes new pyrazolo-pyrimidine derivatives which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: November 14, 2017
    Assignee: Novartis AG
    Inventors: Carole Pissot Soldermann, Jean Quancard, Achim Schlapbach, Oliver Simic, Marina Tintelnot-Blomley, Thomas Zoller
  • Publication number: 20170121335
    Abstract: The present invention describes new pyrazolo-pyrimidine derivatives which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.
    Type: Application
    Filed: May 27, 2015
    Publication date: May 4, 2017
    Applicant: NOVARTIS AG
    Inventors: Carole Pissot Soldermann, Jean Quancard, Achim Schlapbach, Oliver Simic, Marina Tintelnot-Bromley, Thomas Zoller
  • Patent number: 9206232
    Abstract: The present application describes organic compounds of Formula (II) that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: December 8, 2015
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Patent number: 9085555
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: January 2, 2012
    Date of Patent: July 21, 2015
    Assignee: NOVARTIS AG
    Inventors: Eva Altmann, Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Juergen Klaus Maibaum, Nils Ostermann, Jean Quancard, Stefan Andreas Randl, Oliver Simic, Anna Vulpetti, VĂ©ronique Stark-Rogel
  • Publication number: 20140357551
    Abstract: The present application describes organic compounds of Formula (II) that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Applicant: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Patent number: 8840878
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: September 23, 2014
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Patent number: 8613914
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: December 24, 2013
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Patent number: 8512690
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: August 20, 2013
    Assignee: Novartis AG
    Inventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
  • Patent number: 8445527
    Abstract: The present invention provides a method of treating a HCV infection in a subject in need thereof by administering a compound of Formula I: or pharmaceutically acceptable salts thereof or stereoisomers thereof.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: May 21, 2013
    Assignee: Novartis AG
    Inventors: Michael Patane, Prakash Raman, David Thomas Parker, Jiping Fu, Branko Radetich, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng, Trixi Brandl, Francois Lenoir, Pascal Rigollier, Oliver Simic
  • Publication number: 20130034519
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: February 7, 2013
    Inventors: Trixi BRANDL, Prakash RAMAN, Pascal RIGOLLIER, Mohindra SEEPERSAUD, Oliver SIMIC
  • Publication number: 20130022572
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 24, 2013
    Inventors: Trixi BRANDL, Prakash RAMAN, Pascal RIGOLLIER, Mohindra SEEPERSAUD, Oliver SIMIC
  • Publication number: 20120295884
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: January 2, 2012
    Publication date: November 22, 2012
    Applicant: NOVARTIS AG
    Inventors: Eva ALTMANN, Ulrich HOMMEL, Edwige Liliane Jeanne LORTHIOIS, Juergen Klaus MAIBAUM, Nils OSTERMANN, Jean Quancard, Stefan Andreas RANDL, Olivier ROGEL, Oliver SIMIC, Anna VULPETTI, Veronique Stark-Rogel
  • Publication number: 20120231998
    Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Application
    Filed: May 22, 2012
    Publication date: September 13, 2012
    Inventors: Trixi Brandl, Jiping Fu, Francois Lenoir, David Thomas Parker, Michael Patane, Branko Radetich, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic, Aregahegn Yifru, Rui Zheng
  • Patent number: 8211932
    Abstract: The present application describes organic compounds of the Formula I that are useful for the treatment, prevention and/or amelioration of human diseases.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: July 3, 2012
    Assignee: Novartis AG
    Inventors: Michael Patane, Prakash Raman, David Thomas Parker, Jiping Fu, Branko Radetich, Mohindra Seepersaud, Aregahegn Yifru, Rui Zheng, Trixi Brandl, Francois Lenoir, Pascal Rigollier, Oliver Simic
  • Patent number: 8008250
    Abstract: Macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 or 18, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them are presented.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: August 30, 2011
    Assignee: Novartis AG
    Inventors: Andreas Lerchner, Rainer Machauer, Marina Tintelnot-Blomley, Oliver Simic